VEGF and Ang2 are critical factors required for tumor angiogenesis. Combined blockade of VEGF and Ang2 with investigational agents enhances antitumor activity in preclinical studies. Combination of REGN910 with aflibercept warrants further clinical investigation...
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, antiangiogenesis, antitumor, Ang2, Dr. Alshad S. Lalani, REGN910, aflibercept, combination therapy, VEGF, preclinical studies